IMCODE001
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
- NCT03815058 ↗
- Completed
- Genentech, Inc.
- Focused
We haven't built an HCP commentary report on IMCODE001 (autogene cevumeran plus pembrolizumab in previously untreated advanced melanoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMCODE001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Melanoma
- Interventions
- Autogene cevumeran; Pembrolizumab
- Arms
- Safety Run-in Period: Autogene Cevumeran + Pembrolizumab · Experimental
- Randomized Period: Arm A: Pembrolizumab · Active comparator
- Randomized Period: Arm B: Autogene Cevumeran + Pembrolizumab · Experimental
- Enrollment
- 131
- Primary outcomes
- Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization
- Sponsor
- Genentech, Inc. with BioNTech SE
- Start
- Dec 21, 2018
- Primary completion
- Jan 21, 2025
- Results posted
- Yes
- Registry record
- NCT03815058 · updated Jan 30, 2026